{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:37:00Z","timestamp":1792291020578,"version":"4.4.0"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["saudiophthaljournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Journal of Ophthalmology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.sjopt.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T15:31:48Z","timestamp":1488987108000},"page":"99-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization"],"prefix":"10.4103","volume":"31","author":[{"given":"Tariq","family":"Al-Debasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkareem","family":"Al-Bekairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik","family":"Al-Katheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmeylan","family":"Al Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.sjopt.2017.02.008_b0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcrs.2010.12.037","article-title":"Anatomy and physiology of the cornea","volume":"37","author":"DelMonte","year":"2011","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.sjopt.2017.02.008_b0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nri1224","article-title":"Ocular immune privilege: therapeutic opportunities from an experiment of nature","volume":"3","author":"Streilein","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0039-6257(96)00007-0","article-title":"Chemical injuries of the eye: current concepts in pathophysiology and therapy","volume":"41","author":"Wagoner","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0020","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0161-6420(00)00289-X","article-title":"Management of alkali burns: an 11 year retrospective review","volume":"107","author":"Brodovsky","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.sjopt.2017.02.008_b0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00003226-199309000-00003","article-title":"Epithelial basement membrane in alkali-burned corneas in rats. Immunohistochemical study","volume":"12","author":"Saika","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0030","first-page":"3320","article-title":"Expression of collagen I, smooth musclea-actin, and vimentin during the healing of alkali-burned and lacerated corneas","volume":"34","author":"Ishizaki","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization: pathogenesis and inhibition","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0045","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.sjopt.2017.02.008_b0050","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2174\/138955709788922665","article-title":"Treating age-related macular degeneration-interaction of VEGF-antagonists with their target","volume":"9","author":"Klettner","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.sjopt.2017.02.008_b0055","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0060","first-page":"961","article-title":"Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"10.1016\/j.sjopt.2017.02.008_b0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1in human corneas with neovascularization","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.sjopt.2017.02.008_b0080","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.sjopt.2017.02.008_b0085","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/emm.2006.21","article-title":"Inhibition of corneal neovascularization by rapamycin","volume":"38","author":"Kwon","year":"2006","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.sjopt.2017.02.008_b0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/187221309789257450","article-title":"Corneal neovascularization: molecular events and therapeutic options","volume":"3","author":"Shakiba","year":"2009","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.sjopt.2017.02.008_b0105","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0110","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","article-title":"Effect of bevacizumab on corneal neovascularization in experimental rabbit model","volume":"37","author":"Ahmed","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0115","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in woundand inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.sjopt.2017.02.008_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","article-title":"Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease","volume":"56","author":"Tolentino","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.sjopt.2017.02.008_b0135","unstructured":"Avastin (bevacizumab) solution for intravenous infusion prescribing information. <http:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf> [accessed 11 March 2014]."},{"key":"10.1016\/j.sjopt.2017.02.008_b0140","unstructured":"Lucentis (ranibizumab injection) intravitreal injection prescribing information. <http:\/\/www.gene.com\/download\/pdf\/lucentis_prescribing.pdf> [accessed 11 March 2014]."},{"key":"10.1016\/j.sjopt.2017.02.008_b0145","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0150","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.sjopt.2017.02.008_b0155","doi-asserted-by":"crossref","first-page":"26031","DOI":"10.1016\/S0021-9258(18)35712-0","article-title":"Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms","volume":"267","author":"Houck","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.sjopt.2017.02.008_b0160","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen","volume":"293","author":"Chen","year":"1999","journal-title":"J Mol Biol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08977199209023937","article-title":"The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies","volume":"7","author":"Kim","year":"1992","journal-title":"Growth Factors"},{"key":"10.1016\/j.sjopt.2017.02.008_b0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2174\/187152811798104872","article-title":"Aflibercept (VEGF-TRAP): the next anti-VEGF drug","volume":"10","author":"Stewart","year":"2011","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.sjopt.2017.02.008_b0175","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.sjopt.2017.02.008_b0185","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0190","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0195","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0200","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1167\/iovs.09-4571","article-title":"The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency","volume":"51","author":"Lin","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0205","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0215","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0220","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.sjopt.2017.02.008_b0225","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Study: using the internet to assess drug safety worldwide","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"suppl","key":"10.1016\/j.sjopt.2017.02.008_b0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacizumab","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.sjopt.2017.02.008_b0235","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/178132","article-title":"Treatment of corneal neovascularization using anti-VEGF bevacizumab","volume":"2014","author":"Krizova","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0250","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/ICO.0b013e3181e458c5","article-title":"Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition","volume":"30","author":"Chu","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0255","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"88","author":"Zaki","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0260","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0265","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jfo.2010.07.007","article-title":"Sub-conjunctival bevacizumab for corneal neovascularization","volume":"33","author":"Gueudry","year":"2010","journal-title":"J Fr Ophtalmol"},{"issue":"10","key":"10.1016\/j.sjopt.2017.02.008_b0270","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","article-title":"Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization","volume":"30","author":"Yeung","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0275","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0280","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":"Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sjopt.2017.02.008_b0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res"},{"issue":"4","key":"10.1016\/j.sjopt.2017.02.008_b0290","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5935\/0004-2749.20140054","article-title":"Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization","volume":"77","author":"Ozdemir","year":"2014","journal-title":"Arq Bras Oftalmol"},{"issue":"7","key":"10.1016\/j.sjopt.2017.02.008_b0295","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","article-title":"Effect of bevacizumab on corneal neovascularization in experimental rabbit model","volume":"37","author":"Ahmed","year":"2009","journal-title":"Clin Exper Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0300","doi-asserted-by":"crossref","unstructured":"Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011;7;52(12):8718\u20138723.","DOI":"10.1167\/iovs.11-7871"},{"key":"10.1016\/j.sjopt.2017.02.008_b0305","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":"The impact of subconjunctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.sjopt.2017.02.008_b0310","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcjo.2012.12.003","article-title":"Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization","volume":"48","author":"Ozdemir","year":"2013","journal-title":"Can J Ophthalmol"},{"issue":"Suppl 7","key":"10.1016\/j.sjopt.2017.02.008_b0320","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.5301\/ejo.5000050","article-title":"Triple therapy for corneal neovascularization: a case report","volume":"22","author":"Veritti","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0325","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.sjopt.2017.02.008_b0330","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.sjopt.2017.02.008_b0335","doi-asserted-by":"crossref","first-page":"e94205","DOI":"10.1371\/journal.pone.0094205","article-title":"Mechanisms controlling the effects of bevacizumab (Avastin) on the inhibition of early but not late formed corneal neovascularization","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.sjopt.2017.02.008_b0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5301\/ejo.5000391","article-title":"The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model","volume":"24","author":"Liarakos","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.sjopt.2017.02.008_b0345","unstructured":"Rosenfeld PJ. My use of aflibercept in clinical practice. Retina Today 2012; 50."},{"key":"10.1016\/j.sjopt.2017.02.008_b0350","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart","year":"2008","journal-title":"Br J Ophthalmol"}],"container-title":["Saudi Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319453417300310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319453417300310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T13:57:22Z","timestamp":1658757442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319453417300310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1319453417300310"],"URL":"https:\/\/doi.org\/10.1016\/j.sjopt.2017.02.008","relation":{},"ISSN":["1319-4534"],"issn-type":[{"value":"1319-4534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Saudi Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sjopt.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Production and hosting by Elsevier B.V. on behalf of Saudi Ophthalmological Society, King Saud University.","name":"copyright","label":"Copyright"}]}}